MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- SUN PHARMA
SUN PHARMA Share Price (SUNP)
Here is the latest stock price and chart of Sun Pharma. For more details, see the Sun Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Just Released: The No. 1 Stock to Buy in 2020
| Live BSE Quotes | Jan 23, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)449.90 | Open (Rs) 445.25 | High (Rs) 452.00 | Low (Rs) 445.10 |
| % Change0.82 | Volume 64,278 | Value (Rs) 28,916,273 | 52-Week H/L 484.10 / 350.40 |
| Live NSE Quotes | Jan 23, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)449.85 | Open (Rs) 447.20 | High (Rs) 452.20 | Low (Rs) 445.00 |
| % Change0.80 | Volume 1,875,787 | Value (Rs) 843,451,684 | 52-Week H/L 484.25 / 344.55 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 20.16 | P/E Ratio (x) 22.32 | Market Cap (Rs m) 1,082,798.17 | P/BV (x) 2.61 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
SUN PHARMA Share Price Today:
SUN PHARMA last traded price was up 0.8% to Rs 449.9 on the BSE. On the NSE, SUN PHARMA last traded price was up 0.8% to Rs 449.9. The total volume of shares traded was 1.9 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.7%. And the benchmark S&P BSE SENSEX was at 41,386.4 (up 0.7%).
Over the last 30 days, the SUN PHARMA share price is up 5.1%. And over the last one year, SUN PHARMA share price is up 4.4%.
Today's Market
Sensex Ends 271 Points Higher; Capital Goods and Realty Stocks Rally(Closing)
Indian share markets witnessed buying interest during closing hours today and ended higher. Benchmark indices regained momentum amid huge buying seen in capital goods and realty stocks.
Related Views On News
SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)
Aug 14, 2019 | Updated on Aug 14, 2019For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My Latest Stock Recommendation (Fast Profits Daily)
Jan 10, 2020The story behind my latest stock recommendation and an important announcement.
Bet on These Smallcap Stocks for Success in 2020 (Profit Hunter)
Jan 14, 2020The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.